EA200802213A1 - Способы лечения заболеваний крови - Google Patents

Способы лечения заболеваний крови

Info

Publication number
EA200802213A1
EA200802213A1 EA200802213A EA200802213A EA200802213A1 EA 200802213 A1 EA200802213 A1 EA 200802213A1 EA 200802213 A EA200802213 A EA 200802213A EA 200802213 A EA200802213 A EA 200802213A EA 200802213 A1 EA200802213 A1 EA 200802213A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
treating blood
blood diseases
diseases
treating
Prior art date
Application number
EA200802213A
Other languages
English (en)
Inventor
Сузан П. Перрине
Роберт М. Уилльямс
Регина Бояцек
Томас Дж. Грешок
Original Assignee
Химекуэст Фармасьютикалз, Инк.
Колорадо Стейт Юниверсити Рисёрч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Химекуэст Фармасьютикалз, Инк., Колорадо Стейт Юниверсити Рисёрч Фаундейшн filed Critical Химекуэст Фармасьютикалз, Инк.
Publication of EA200802213A1 publication Critical patent/EA200802213A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles

Abstract

Описаны способы лечения заболеваний крови с использованием соединений формул (II), (I), (III) или (II'):
EA200802213A 2006-05-09 2007-05-09 Способы лечения заболеваний крови EA200802213A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79905406P 2006-05-09 2006-05-09
PCT/US2007/011335 WO2007133653A2 (en) 2006-05-09 2007-05-09 Methods for treating blood disorders

Publications (1)

Publication Number Publication Date
EA200802213A1 true EA200802213A1 (ru) 2009-10-30

Family

ID=38626483

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200802213A EA200802213A1 (ru) 2006-05-09 2007-05-09 Способы лечения заболеваний крови

Country Status (9)

Country Link
US (2) US20080075692A1 (ru)
EP (1) EP2023913A2 (ru)
JP (1) JP2009536659A (ru)
CN (1) CN101489544A (ru)
AU (1) AU2007249827A1 (ru)
BR (1) BRPI0713096A2 (ru)
CA (1) CA2652235A1 (ru)
EA (1) EA200802213A1 (ru)
WO (1) WO2007133653A2 (ru)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2324426A1 (en) 1998-02-11 1999-08-19 Douglas V. Faller Compositions and methods for the treatment of cystic fibrosis
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20160137665A (ko) 2005-11-23 2016-11-30 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
NZ707292A (en) * 2006-12-18 2017-06-30 Acceleron Pharma Inc Activin-actrii antagonists and uses for increasing red blood cell levels
AU2008211007B2 (en) * 2007-02-01 2013-09-19 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for treating or preventing breast cancer
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CA3039330C (en) * 2007-02-09 2021-11-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
CN107412734A (zh) * 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
US8741966B2 (en) 2007-11-09 2014-06-03 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
KR20230085944A (ko) 2008-03-18 2023-06-14 아레나 파마슈티칼스, 인크. 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제
EP3363453A1 (en) * 2008-06-26 2018-08-22 Acceleron Pharma Inc. Soluble actriia as activin-actriia antagonist for use in treating anemia or bone-related disorders
EP3620795A1 (en) * 2008-06-26 2020-03-11 Acceleron Pharma Inc. Antagonists of soluble activin-actriia and uses for increasing red blood cell levels
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
JP5922928B2 (ja) 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを高めるためのｇｄｆトラップの使用
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
BRPI0921369B8 (pt) 2008-11-26 2021-05-25 Arena Pharm Inc composto modulador do receptor de prostaciclina (pgi2), sua composição, sua composição farmacêutica, seus usos, bem como processos para a preparação das referidas composições
DK2370413T3 (en) 2008-12-08 2015-11-02 Arena Pharm Inc Modulators of prostacyclin (PG12) receptor, which can be used for the treatment of disorders related to this
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc METHODS FOR INCREASING ADIPONECTIN
JP5843755B2 (ja) 2009-05-08 2016-01-13 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 心血管性、代謝性および炎症性疾患領域に関する疾患の処置のための多価不飽和脂肪酸
EP2440576A4 (en) 2009-06-08 2013-11-20 Acceleron Pharma Inc PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
AU2010263182B2 (en) 2009-06-12 2016-05-12 Acceleron Pharma Inc. Truncated ActRIIB-Fc fusion proteins
AU2010292203A1 (en) * 2009-09-09 2012-04-12 Acceleron Pharma Inc. ActRIIb antagonists and dosing and uses thereof
CN101653449B (zh) * 2009-09-11 2012-05-23 南京大学 ADDA和/或DMTA在制备提高γ-珠蛋白表达量的药物中的应用
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
US20110129469A1 (en) * 2009-11-03 2011-06-02 Acceleron Pharma Inc. Methods for treating fatty liver disease
CA2781152A1 (en) * 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CN102802412A (zh) * 2009-12-08 2012-11-28 海玛奎斯特医药公司 用于治疗红细胞病症的方法及低剂量方案
US20110177033A1 (en) * 2010-01-20 2011-07-21 Academia Sinica Ras responsive element binding protein 1 (rreb1) as a therapeutic target for thalassemias and sickle cell anemia
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
SG190114A1 (en) 2010-11-05 2013-07-31 Pronova Biopharma Norge As Methods of treatment using lipid compounds
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
US9018176B2 (en) 2010-12-02 2015-04-28 Susan Perrine Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders
ES2884095T3 (es) 2012-11-02 2021-12-10 Celgene Corp Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
MX2015011074A (es) 2013-02-28 2016-03-09 Pronova Biopharma Norge As Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma.
PE20160874A1 (es) 2013-05-28 2016-09-04 Astrazeneca Ab Compuestos quimicos
CA3120111A1 (en) * 2013-08-20 2015-02-26 Phoenicia Biosciences, Inc. Chemical inducers of fetal hemoglobin
BR122023023170A2 (pt) 2014-06-13 2024-02-20 Acceleron Pharma Inc. Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
WO2016065103A1 (en) 2014-10-23 2016-04-28 Arena Pharmaceuticals, Inc. Method of treating conditions related to the pgi2 receptor
MD4801C1 (ru) 2014-12-03 2022-10-31 Celgene Corporation Антагонисты активина-ActRII и их применение для лечения миелодиспластических синдромов
JP6784696B2 (ja) 2015-04-28 2020-11-11 プロノヴァ バイオファーマ ノルゲ エーエス 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び／又は治療のための使用
ES2897024T3 (es) 2017-03-01 2022-02-28 Arena Pharm Inc Composiciones que comprenden agonistas del receptor de PGI2 y procesos para la preparación de las mismas
EP3681885B1 (en) 2017-09-15 2024-02-28 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
WO2019084402A1 (en) * 2017-10-27 2019-05-02 St. Jude Children's Research Hospital METHOD OF TREATMENT OF THALASSEMIA
KR20200096791A (ko) 2017-12-06 2020-08-13 바스프 에이에스 비알콜성 지방간염 치료용 지방산 유도체
WO2020006483A1 (en) 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibiting creb binding protein (cbp)
MX2021014639A (es) 2019-05-31 2022-04-06 Viracta Subsidiary Inc Metodos para tratar canceres asociados con virus con inhibidores de la histona deacetilasa.
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
CN112812006A (zh) * 2020-12-30 2021-05-18 广州城市职业学院 一种对羟基苯乙酮半抗原、人工抗原及其合成方法与应用
WO2023069529A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704402A (en) * 1982-06-12 1987-11-03 University Of Pittsburgh Method of treating sickle cell anemia
US5025029A (en) * 1986-10-10 1991-06-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
GB8912700D0 (en) * 1989-06-02 1989-07-19 Shell Int Research Herbicidal compounds
DE68914197T2 (de) * 1988-06-20 1994-11-10 Kumiai Chemical Industry Co Alkansäurederivate und herbizide Mittel.
SG86966A1 (en) * 1988-11-29 2002-03-19 Childrens Hosp Medical Center Medicament for augmenting fetal hemoglobin
US5569675A (en) * 1994-03-07 1996-10-29 Bar Ilan University Methods of using carboxylic acid esters to increase fetal-hemoglobin levels
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5939456A (en) * 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders

Also Published As

Publication number Publication date
US8759378B2 (en) 2014-06-24
WO2007133653A2 (en) 2007-11-22
US20090137567A1 (en) 2009-05-28
JP2009536659A (ja) 2009-10-15
CA2652235A1 (en) 2007-11-22
WO2007133653A3 (en) 2008-01-24
CN101489544A (zh) 2009-07-22
US20080075692A1 (en) 2008-03-27
EP2023913A2 (en) 2009-02-18
BRPI0713096A2 (pt) 2012-10-16
AU2007249827A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
EA200802213A1 (ru) Способы лечения заболеваний крови
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
EA201170521A1 (ru) Новые соединения
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
UA85559C2 (en) Aminobenzophenone compounds
EA200501430A1 (ru) Лиганды каннабиноидных рецепторов и их применение
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA200700225A1 (ru) Аналоги тетрапептида
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
TW200510333A (en) Benzimidazole compounds
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
EA200702363A1 (ru) Новые лиганды гистамина h-рецептора и их терапевтические применения
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии